Metformin therapy in patients with chronic kidney disease

Diabetes, Obesity and Metabolism

Volumn 14, Issue 10, 2012, Pages 963-965

  Duong, J K ^a,b   Roberts, D M ^b   Furlong, T J ^b   Kumar, S S ^a,b   Greenfield, J R ^b,c   Kirkpatrick, C M ^d   Graham, G G ^a,b   Williams, K M ^a,b   Day, R O ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Diabetic nephropathy; Metformin; Pharmacokinetics; Pharmacology; Type 2 diabetes

Indexed keywords

FRUCTOSAMINE; HEMOGLOBIN A1C; LACTIC ACID; METFORMIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; LACTIC ACIDOSIS; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS;

EID: 84865998218     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01617.x     Document Type: Letter

References (12)

1. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981; 12: 235-246.
2. Davis TM, Jackson D, Davis WA, Bruce DG, Chubb P. The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study. Br J Clin Pharmacol 2001; 52: 137-144.
3. National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians, 2008.
4. Rossi S. Australian Medicines Handbook 2011. Adelaide: Australian Medicines Handbook Pty Ltd, 2011.
5. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005; 44: 721-729.
6. Zarghi A, Foroutan SM, Shafaati A, Khoddam A. Rapid determination of metformin in human plasma using ion-pair HPLC. J Pharm Biomed Anal 2003; 31: 197-200.
7. Frid A, Sterner GN, Londahl M, et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care 2010; 33: 1291-1293.
8. Lalau JD, Lemaire-Hurtel AS, Lacroix C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Investig 2011; 31: 435-438.
9. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50: 81-98.
10. Shu Y, Brown C, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273-280.
11. Vasisht KP, Chen SC, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab 2010; 12: 1079-1083.
12. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011; 118: c380-c383.